KKR invests $100m in Nordic Bioscience

The GP will acquire the stake from existing shareholders, including founder Claus Christiansen, and will support the company in accelerating its global growth.

KKR is investing from Health Care Strategic Growth Fund, which held a final close in November 2017 on $1.45bn.

The GP has deployed around $3bn in the Nordic region across different strategies, including private equity. Its recent investments include Caruna, Wolt, Visma, Välinge, Mehilainen, Sector Alarm, and Söderberg & Partners.

Company
Founded in 1991 in Herlev, Nordic Bioscience is a biotech company that specialises in pre-clinical and clinical drug development using biomarker technologies. It liaises with biotech and pharmaceutical clients to identify projects most suitable for clinical development. 

According to its annual report, Nordic Bioscience in 2019 generated an operating profit of DKK 43.8m (€5.8m). It has more than 180 employees. 

People 
Nordic Bioscience – Morten Karsdal (CEO); Claus Christiansen (founder, chairman). 
KKR – Kugan Sathiyanandarajah (managing director); Anuv Ratan (principal). 

Advisers
Company – Nordic M&A (M&A).
Equity – Kromann Reumert (legal). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics
• Healthcare
• KKR
• healthcare
• Denmark